NRIX Stock Forecast & Price Target

Nurix Therapeutics is attractive because its lead BTK degrader, bexobrutideg, is advancing through registrational and combination studies with encouraging efficacy and safety signals in CLL, while planned expansion into MS and CSU broadens the addressable opportunity. The company’s 3Q26 results were strong, with $673.1M in collaboration and license revenue, $4.73 in net gain per share, and $1.1B in cash and equivalents, which supports a runway into 2H29 and reduces financing risk. Its partnerships with Roche, Sanofi, Gilead, and Pfizer validate the platform, while multiple upcoming catalysts across 2026 and beyond offer additional de-risking and upside from a diversified targeted protein degradation pipeline.

Nurix Therapeutics is viewed negatively because the downside case hinges on bexobrutideg failing to show competitive durability or revealing a potential safety concern, either of which could preclude further development. That outcome would materially weaken confidence in the company’s lead program and suggest the pipeline may not support meaningful long-term value creation beyond its existing cash resources. In that scenario, the stock could trade closer to the company’s net cash position, implying minimal value is being ascribed to the broader clinical-stage portfolio.